Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme, BD Technologies Expand HT Assay Development Partnership

NEW YORK, March 2 (GenomeWeb News) - Tranzyme Pharma today said that it has expanded a strategic alliance it began in 2002 with BD Technologies, a unit of Becton, Dickinson and Company.

The collaboration is focused on the development and commercialization of high-throughput assays for drug discovery.

Under the expanded alliance, BD will continue to receive access to Tranzyme's TranzVector and TExT proprietary gene delivery and expression technologies, and the two companies will also jointly explore the use of Tranzyme's technologies in specific cell types of interest to BD.

BD will provide R&D funding to Tranzyme and will have rights to market any commercial products that result from the use of Tranzyme's technology. BD said it would pay Tranzyme royalties on the sale of these products.

Other financial details of the agreement were not disclosed.

Tranzyme is a member of the BD Technologies BioVenture Center Incubator in Research Triangle Park, NC.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.